The following brief review of the present status of the materia medica of the digitalis group and its relation to therapeutics has been prepared at the request of Prof. Julius Stieglitz, chairman of a committee on synthetic drugs, appointed by the National Research Council, because of the present want of many preparations of this group that have come into more or less widespread use.
All of the members of this group, including many crude drugs and their galenic preparations, as well as glucosidal active principles, exert a qualitatively similar therapeutic action on the heart when they are brought into the blood stream; but the various members of the group vary enormously in their activity and in the rate of their absorption from the alimentary tract.
These differences in behavior of the different members of the group have resulted in the development of faith in one or the other of the
HATCHER RA. DIGITALIS THERAPY AND THE PRESENT SHORTAGE IN DRUGS. JAMA. 1917;LXIX(18):1524–1525. doi:10.1001/jama.1917.25910450005015a
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: